Literature DB >> 21244611

Early vs delayed radical cystectomy for 'high-risk' carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival.

Wolfgang Jäger1, Christian Thomas, Silke Haag, Christian Hampel, Alice Salzer, Joachim W Thüroff, Christoph Wiesner.   

Abstract

OBJECTIVE: •To analyze the impact of a delayed radical cystectomy (rCx) and clinical variables on cancer-specific survival (CSS) in patients presenting 'high-risk' carcinoma not invading bladder muscle (nmiBCA). PATIENTS AND METHODS: •Between 1989 and 2006, 278 patients who presented 'high-risk' nmiBCA finally underwent rCx in our institution. •CSS was correlated with clinical variables such as the number of transurethral resections of the bladder (TURBs), interval between first TURB and rCx, adjuvant therapies, tumour upstaging at rCx, tumour stage and lymph node (LN) status.
RESULTS: •The overall 5- and 10-year CSS was 82% and 76%, respectively. Significant correlations were found between the 5-year CSS and categorized number of TURBs (≤2 vs >2: 88% vs 71%; P= 0.001), interval between first TURB and rCx (≤4 months vs >4 months: 86% vs 77%; P= 0.04), adjuvant therapies (no vs yes: 86% vs 66%; P= 0.001), tumour upstaging at rCx (no vs yes: 89% vs 67%; P < 0.001), tumour stage at rCx (bladder confined vs non-confined: 88% vs 56%; P < 0.001) and LN status (no vs yes: 88% vs 36%; P < 0.001). •Multivariate analysis identified categorized number of TURBs (hazard ratio, HR, 0.14; 95% CI, 0.07-0.44; P < 0.001), categorized interval between first TURB and rCx (HR, 3.27; 95% CI, 1.24-8.59; P= 0.017), LN status (HR, 0.13; 95% CI, 0.06-0.26; P < 0.001) and tumour stage at rCx (HR, 0.49; 95% CI, 0.26-0.92; P= 0.03) as independent risk factors for CSS.
CONCLUSION: •Delay of rCx in 'high-risk' nmiBCA deteriorates CSS and should be avoided. The number of TURBs and the interval between first TURB and rCx are causative factors for delayed rCx and are independently correlated with CSS.
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2011        PMID: 21244611     DOI: 10.1111/j.1464-410X.2010.09980.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  16 in total

Review 1.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

2.  Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes?

Authors:  Ahmed F Kotb; Evan Kovac; Wassim Kassouf; Joe Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; David Bell; Darrel Drachenberg; Armen G Aprikian
Journal:  World J Urol       Date:  2012-12       Impact factor: 4.226

Review 3.  Guideline of guidelines: non-muscle-invasive bladder cancer.

Authors:  Solomon L Woldu; Aditya Bagrodia; Yair Lotan
Journal:  BJU Int       Date:  2017-01-24       Impact factor: 5.588

Review 4.  Survival Outcomes of Early versus Deferred Cystectomy for High-Grade Non-Muscle-Invasive Bladder Cancer: A Systematic Review.

Authors:  Jonathan C M Wan
Journal:  Curr Urol       Date:  2020-06-23

5.  Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version.

Authors:  Bimal Bhindi; Ronald Kool; Girish S Kulkarni; D Robert Siemens; Armen G Aprikian; Rodney H Breau; Fadi Brimo; Adrian Fairey; Christopher French; Nawar Hanna; Jonathan I Izawa; Louis Lacombe; Victor McPherson; Ricardo A Rendon; Bobby Shayegan; Alan I So; Alexandre R Zlotta; Peter C Black; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2021-08       Impact factor: 1.862

6.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

7.  Timing of radical cystectomy in Central Europe - multicenter study on factors influencing the time from diagnosis to radical treatment of bladder cancer patients.

Authors:  Sławomir Poletajew; Bogdan Braticevici; Antonín Brisuda; Victor Cauni; Viacheslav Grygorenko; Martyn-Zenovii Lesnyak; Janusz Lisiński; Cristian Persu; Kacper Renk; Piotr Radziszewski
Journal:  Cent European J Urol       Date:  2014-12-17

Review 8.  How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

Authors:  Seok Joong Yun; Seon-Kyu Kim; Wun-Jae Kim
Journal:  Investig Clin Urol       Date:  2016-06-10

Review 9.  Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.

Authors:  Mario Pones; David D'Andrea; Keiichiro Mori; Mohammad Abufraj; Marco Moschini; Eva Comperat; Shahrokh F Shariat
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

10.  Oncological Outcome of Primary and Secondary Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.

Authors:  Peng Ge; Li Wang; Meng Lu; Lijun Mao; Wang Li; Rumin Wen; Jian Lin; Junqi Wang; Jiacun Chen
Journal:  Sci Rep       Date:  2018-05-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.